Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA updates GMPs

This article was originally published in The Tan Sheet

Executive Summary

FDA revises its good manufacturing practice regulations for finished pharmaceuticals to clarify some of the requirements and harmonize them with other FDA standards and international GMPs as part of its first phase of its incremental approach to modifying the GMPs for finished drugs, according to a final rule published in the Sept. 8 Federal Register. Specifically, the rule revises requirements related to aseptic processing, verification of performance of operations by a second individual and use of asbestos filters. The rule applies to all finished pharmaceuticals, both under new drug applications and OTC monographs. "We are pleased to see the agency updating GMPs and feel it is important they continue to do so," commented Elizabeth Funderburk, Consumer Products Healthcare Association director of communications

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102096

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel